CEO of China Operations
Mr. Hong Zhao was appointed as Chief Executive Officer China Operations of Sciclone Pharmaceuticals, Inc., effective April 01, 2013. Mr. Zhao joined SciClone as Chief Executive Officer, China Operations, in April 2013. Prior to SciClone, from 2011 to 2013, Mr. Zhao served as Executive Vice President of Simcere Pharmaceutical Group, a manufacturer and supplier of pharmaceuticals in China, where he was responsible for all business operations and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development. Prior to Simcere, from 1999 to 2011, Mr. Zhao held various positions at Novartis China, a health care products company, including most recently, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai
Age: 50 CEO Since 2013
|Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School in Shanghai.|
Hong Zhao Latest Insider Trades
The company has return on total asset (ROA)
of 0.15 %
which means that it generated profit of $0.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of 0.18 %
meaning that it created $0.18 on every $100 dollars invested by stockholders.
The company currently holds 1.65 M in liabilities with Debt to Equity (D/E) ratio of 0.01 which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals Inc has Current Ratio of 7.33 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals Inc (SCLN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 590 people. SciClone Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare
with concentration in Pharmaceuticals And Biosciences